| Date | Title | Description | |
|---|---|---|---|
| 03 Nov 2021 | On buy-back programmes | The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. | Download |
| 16 Jul 2021 | On Corporate Governance | ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company | Download |
| 22 Jun 2021 | On significant placements in financial instruments | Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. | Download |
| 22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
| 29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors | Download |
| 23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
| 21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
| 15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
| 14 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 10 May 2018 | Otros sobre negocio y situación financiera | Update pivotal PRISMA-3 study of DORIA® (Risperidone ISM®) | Download |
| 25 Apr 2018 | Información sobre resultados | ROVI releases the press release related to the 2018 first quarter financial results | Download |
| 25 Apr 2018 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI informs about the call for the 2018 Ordinary General Shareholders Meeting | Download |
| 25 Apr 2018 | Información sobre resultados | ROVI releases the 2018 first quarter results presentation | Download |
| 04 Apr 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2018 | Download |